Eric M Bachelder

List of Publications by Year
in descending order

68 papers	3,325 citations	147801 31 h-index	149698 56 g-index
68 all docs	68 docs citations	68 times ranked	3641 citing authors

#	Article	IF	Citations
1	Delivery strategies for cancer vaccines and immunoadjuvants. , 2022, , 359-408.		1
2	Nano/microparticle Formulations for Universal Influenza Vaccines. AAPS Journal, 2022, 24, 24.	4.4	4
3	Development of an Intranasal Gel for the Delivery of a Broadly Acting Subunit Influenza Vaccine. ACS Biomaterials Science and Engineering, 2022, 8, 1573-1582.	5.2	8
4	STING agonist-containing microparticles improve seasonal influenza vaccine efficacy and durability in ferrets over standard adjuvant. Journal of Controlled Release, 2022, 347, 356-368.	9.9	13
5	Metalâ€“Organic Coordination Polymer for Delivery of a Subunit Broadly Acting Influenza Vaccine. ACS Applied Materials & Interfaces, 2022, 14, 28548-28558.	8.0	15
6	Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis. ACS Biomaterials Science and Engineering, 2021, 7, 1725-1741.	5.2	14
7	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Advanced Drug Delivery Reviews, 2021, 169, 168-189.	13.7	62
8	Merozoite surface protein 2 adsorbed onto acetalated dextran microparticles for malaria vaccination. International Journal of Pharmaceutics, 2021, 593, 120168.	5.2	11
9	Considerations for Size, Surface Charge, Polymer Degradation, Coâ€Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases. Advanced NanoBiomed Research, 2021, 1, 2000041.	3.6	37
10	STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFNâ€“Dependent and â€“Independent Immune-Regulatory Pathways. Journal of Immunology, 2021, 206, 2015-2028.	0.8	18
11	Historical Perspective of Clinical Nano and Microparticle Formulations for Delivery of Therapeutics. Trends in Molecular Medicine, 2021, 27, 516-519.	6.7	17
12	Dexamethasone and Fumaric Acid Ester Conjugate Synergistically Inhibits Inflammation and NF-ÎºB in Macrophages. Bioconjugate Chemistry, 2021, 32, 1629-1640.	3.6	8
13	Overcoming reduced antibiotic susceptibility in intracellular<i>Salmonella enterica</i>serovar Typhimurium using AR-12. FEMS Microbiology Letters, 2021, 368, .	1.8	1
14	Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 13160.	4.1	17
15	Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications. ACS Applied Materials & Interfaces, 2020, 12, 38950-38961.	8.0	10
16	Polymeric Biomaterial Scaffolds for Tumoricidal Stem Cell Glioblastoma Therapy. ACS Biomaterials Science and Engineering, 2020, 6, 3762-3777.	5.2	14
17	Glycolipid-mediated basophil activation in alpha-gal allergy. Journal of Allergy and Clinical Immunology, 2020, 146, 450-452.	2.9	27
18	Formulation of host-targeted therapeutics against bacterial infections. Translational Research, 2020, 220, 98-113.	5.0	11

#	Article	IF	Citations
19	Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy. Journal of Controlled Release, 2020, 323, 282-292.	9.9	28
20	Impact of composite scaffold degradation rate on neural stem cell persistence in the glioblastoma surgical resection cavity. Materials Science and Engineering C, 2020, 111, 110846.	7.3	8
21	Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma. ACS Applied Materials & Interfaces, 2020, 12, 19345-19356.	8.0	32
22	Oxidation-Sensitive Dextran-Based Polymer with Improved Processability through Stable Boronic Ester Groups. ACS Applied Bio Materials, 2019, 2, 3755-3762.	4.6	8
23	Electrospray for generation of drug delivery and vaccine particles applied in vitro and in vivo. Materials Science and Engineering C, 2019, 105, 110070.	7.3	57
24	Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 10, 125-132.	3.4	12
25	A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity. Biomaterials, 2019, 205, 94-105.	11.4	67
26	Drug Delivery for Cancer Immunotherapy and Vaccines. Pharmaceutical Nanotechnology, 2019, 6, 232-244.	1.5	18
27	Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses. Journal of Controlled Release, 2018, 273, 147-159.	9.9	61
28	Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection. Molecular Pharmaceutics, 2018, 15, 1309-1318.	4.6	38
29	A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. Journal of Controlled Release, 2018, 270, 1-13.	9.9	119
30	A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1â€"insensitive models of triple-negative breast cancer. JCI Insight, 2018, 3, .	5.0	175
31	Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy. Journal of Controlled Release, 2018, 289, 114-124.	9.9	57
32	Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. Molecular Pharmaceutics, 2018, 15, 4933-4946.	4.6	64
33	Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles. International Journal of Pharmaceutics, 2018, 552, 371-377.	5.2	7
34	In Vivo and Cellular Trafficking of Acetalated Dextran Microparticles for Delivery of a Host-Directed Therapy for <i>Salmonella enterica</i> Serovar Typhi Infection. Molecular Pharmaceutics, 2018, 15, 5336-5348.	4.6	16
35	Prevention of Type 1 Diabetes with Acetalated Dextran Microparticles Containing Rapamycin and Pancreatic Peptide P31. Advanced Healthcare Materials, 2018, 7, e1800341.	7.6	24
36	PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2017, 198, 1439-1451.	0.8	57

#	Article	IF	Citations
37	Coâ€Delivery of Disease Associated Peptide and Rapamycin via Acetalated Dextran Microparticles for Treatment of Multiple Sclerosis. Advanced Biology, 2017, 1, 1700022.	3.0	18
38	Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production. Pharmaceutical Research, 2017, 34, 419-426.	3.5	22
39	Acetalated Dextran: A Tunable and Acid-Labile Biopolymer with Facile Synthesis and a Range of Applications. Chemical Reviews, 2017, 117, 1915-1926.	47.7	113
40	Microparticles formulated from a family of novel silylated polysaccharides demonstrate inherent immunostimulatory properties and tunable hydrolytic degradability. Journal of Materials Chemistry B, 2016, 4, 4302-4312.	5.8	5
41	Saquinavir Loaded Acetalated Dextran Microconfetti â€“ a Long Acting Protease Inhibitor Injectable. Pharmaceutical Research, 2016, 33, 1998-2009.	3.5	12
42	Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational <i>Bacillus Anthracis</i> Exposure. Advanced Healthcare Materials, 2016, 5, 2617-2627.	7.6	42
43	Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight. International Journal of Pharmaceutics, 2016, 512, 147-157.	5.2	37
44	Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge. Antimicrobial Agents and Chemotherapy, 2016, 60, 2052-2062.	3.2	18
45	One Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading. Molecular Pharmaceutics, 2016, 13, 92-99.	4.6	26
46	Chemically modified inulin microparticles serving dual function as a protein antigen delivery vehicle and immunostimulatory adjuvant. Biomaterials Science, 2016, 4, 483-493.	5.4	22
47	A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by <i>Leishmania donovani</i>. ACS Infectious Diseases, 2015, 1, 497-506.	3.8	18
48	Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases. Pharmaceutical Nanotechnology, 2015, 3, 85-100.	1.5	5
49	Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection. International Journal of Pharmaceutics, 2014, 477, 334-343.	5.2	29
50	Liposomal resiquimod for the treatment of Leishmania donovani infection. Journal of Antimicrobial Chemotherapy, 2014, 69, 168-175.	3.0	37
51	Treatment of Experimental Autoimmune Encephalomyelitis by Codelivery of Disease Associated Peptide and Dexamethasone in Acetalated Dextran Microparticles. Molecular Pharmaceutics, 2014, 11, 828-835.	4.6	57
52	Electrospray Encapsulation of Toll-Like Receptor Agonist Resiquimod in Polymer Microparticles for the Treatment of Visceral Leishmaniasis. Molecular Pharmaceutics, 2013, 10, 1045-1055.	4.6	72
53	Delivery of host cell-directed therapeutics for intracellular pathogen clearance. Expert Review of Anti-Infective Therapy, 2013, 11, 1225-1235.	4.4	22
54	Rapid Vaccination Using an Acetalated Dextran Microparticulate Subunit Vaccine Confers Protection Against Triplicate Challenge by Bacillus Anthracis. Pharmaceutical Research, 2013, 30, 1349-1361.	3.5	30

#	Article	IF	Citations
55	Electrospun Acetalated Dextran Scaffolds for Temporal Release of Therapeutics. Langmuir, 2013, 29, 7957-7965.	3.5	29
56	Efficient Delivery of the Toll-like Receptor Agonists Polyinosinic:Polycytidylic Acid and CpG to Macrophages by Acetalated Dextran Microparticles. Molecular Pharmaceutics, 2013, 10, 2849-2857.	4.6	48
57	Synthesis and Characterization of Acetalated Dextran Polymer and Microparticles with Ethanol as a Degradation Product. ACS Applied Materials & Interfaces, 2012, 4, 4149-4155.	8.0	78
58	Synthesis, Optimization, and Characterization of Camptothecin-Loaded Acetalated Dextran Porous Microparticles for Pulmonary Delivery. Molecular Pharmaceutics, 2012, 9, 290-298.	4.6	61
59	Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. International Journal of Pharmaceutics, 2012, 422, 356-363.	5.2	55
60	Enhanced stability of horseradish peroxidase encapsulated in acetalated dextran microparticles stored outside cold chain conditions. International Journal of Pharmaceutics, 2012, 431, 101-110.	5.2	50
61	Acetalâ€Modified Dextran Microparticles with Controlled Degradation Kinetics and Surface Functionality for Gene Delivery in Phagocytic and Nonâ€Phagocytic Cells. Advanced Materials, 2010, 22, 3593-3597.	21.0	101
62	In Vitro Analysis of Acetalated Dextran Microparticles as a Potent Delivery Platform for Vaccine Adjuvants. Molecular Pharmaceutics, 2010, 7, 826-835.	4.6	118
63	Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5497-5502.	7.1	259
64	Chemoselective Ligation in the Functionalization of Polysaccharide-Based Particles. Journal of the American Chemical Society, 2009, 131, 10360-10361.	13.7	64
65	Fully Acid-Degradable Biocompatible Polyacetal Microparticles for Drug Delivery. Bioconjugate Chemistry, 2008, 19, 911-919.	3.6	160
66	Acid-Degradable Polyurethane Particles for Protein-Based Vaccines: Biological Evaluation and in Vitro Analysis of Particle Degradation Products. Molecular Pharmaceutics, 2008, 5, 876-884.	4.6	49
67	Acetal-Derivatized Dextran: An Acid-Responsive Biodegradable Material for Therapeutic Applications. Journal of the American Chemical Society, 2008, 130, 10494-10495.	13.7	403
68	'Educated' dendritic cells act as messengers from memory to naive T helper cells. Nature Immunology, 2004, 5, 615-622.	14.5	129